...
首页> 外文期刊>Biochemical and Biophysical Research Communications >Association of angiotensin II receptor 1 and lectin-like oxidized low-density lipoprotein receptor-1 mediates the cardiac hypertrophy induced by oxidized low-density lipoprotein
【24h】

Association of angiotensin II receptor 1 and lectin-like oxidized low-density lipoprotein receptor-1 mediates the cardiac hypertrophy induced by oxidized low-density lipoprotein

机译:血管紧张素II受体1和凝集素的氧化低密度脂蛋白受体-1介导通过氧化低密度脂蛋白诱导的心脏肥大介导的心脏肥大

获取原文
获取原文并翻译 | 示例
           

摘要

To date the molecular mechanism of cardiac hypertrophy has not been completely elucidated. Since oxidized low-density lipoprotein (ox-LDL) is considered a risk marker for early ventricular remodeling, we speculated that ox-LDL may be related to cardiac hypertrophy. We observed the significantly upregulation of plasma ox-LDL and hypertrophic responses, such as cardiomyocyte size and specific gene expressions in Apo Er-/- mice fed with high fat diet, accompanied by the upregulation of AT1-R and lectinlike oxidized low-density protein receptor 1 (LOX-1). Ox-LDL treatment with neonatal rat cardiomyocyte for 24 h significantly induced similar hypertrophic responses and also upregulation of AT1-R and LOX-1. The analysis of co-immunoprecipitation and the bimolecular fluorescence complementation assay proved that LOX-1 and AT1-R could directly bind together in the presence of ox-LDL, suggesting a critical role of the association between LOX-I and AT1-R in ox-LDL-induced cardiac hypertrophy. Furthermore, we found that the AT1-R blocker Losartan and LOX-1 neutralizing antibody through inhibiting AT1-R or LOX-I could both decline ox-LDL-induced hypertrophic responses whereas angiotensin converting enzyme inhibitor Enalapril only partially inhibited the responses stimulated by ox-LDL. These findings suggested that ox-LDL could induce cardiac hypertrophy through the direct association of AT1-R and LOX-1. (C) 2017 Elsevier Inc. All rights reserved.
机译:迄今为止,心脏肥大的分子机制尚未完全阐明。由于氧化低密度脂蛋白(OX-LDL)被认为是早期心室重塑的风险标记,我们推测毒蛇-LDL可能与心脏肥大有关。我们观察到血浆OX-LDL和肥厚反应的显着上调,例如在高脂肪饮食中喂养的APO ER / - 小鼠中的心肌细胞大小和特异性基因表达,伴随着AT1-R和Lecclike氧化低密度蛋白的上调受体1(LOX-1)。用新生儿大鼠心肌细胞治疗24小时的OX-LDL治疗显着诱导了类似的肥大反应,也是AT1-R和LOX-1的上调。共免疫沉淀和双分子荧光互补测定的分析证明,LOX-1和AT1-R可以在OX-LDL存在下直接结合在一起,表明LOX-I和AT1-R之间的关键作用-LDL诱导的心脏肥大。此外,我们发现AT1-R阻滞剂氯沙坦和LOX-1通过抑制AT1-R或LOX-1中和抗体可以均下降ox-LDL诱导的肥厚反应,而血管紧张素转化酶抑制剂enalapril仅部分抑制牛刺激的反应-LDL。这些发现表明,OX-LDL可以通过AT1-R和LOX-1的直接关联诱导心脏肥大。 (c)2017年Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号